Spotlight On ALK+ mNSCLC

ALK+ metastatic non-small cell lung cancer (mNSCLC) is a distinct subtype of lung cancer driven by alterations in the anaplastic lymphoma kinase (ALK) gene. While advances in precision medicine have transformed treatment options and outcomes, patients and healthcare professionals continue to face important questions around diagnosis, treatment selection, disease monitoring, resistance, and long-term management.

Here to help shed light on those key questions is our Spotlight On ALK+ Metastatic Non-Small Cell Lung Cancer series, where you’ll find expert insights on the latest clinical insights, evolving treatment landscape, and real-world care considerations.